Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder

Go back to Daré Bioscience Announces Initiation of Phase 2b RESPOND Study of Sildenafil Cream, 3.6% in Women with Female Sexual Arousal Disorder
(NASDAQ: DARE) Delayed: 1.38 +0.06 (4.55%)
Previous Close $1.32    52 Week High
Open $1.34    52 Week Low
Day High $1.38    P/E N/A 
Day Low $1.33    EPS
Volume 592,401